Skandinaviska Enskilda Banken AB publ Takes $893,000 Position in Geron Co. (NASDAQ:GERN)

Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Geron Co. (NASDAQ:GERN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 262,649 shares of the biopharmaceutical company's stock, valued at approximately $893,000.

A number of other institutional investors also recently bought and sold shares of the business. Los Angeles Capital Management LLC purchased a new position in shares of Geron during the third quarter worth about $178,000. Empowered Funds LLC acquired a new position in shares of Geron in the third quarter valued at approximately $67,000. First Turn Management LLC purchased a new stake in shares of Geron during the third quarter worth approximately $14,187,000. Intech Investment Management LLC acquired a new stake in shares of Geron during the third quarter worth $1,102,000. Finally, Charles Schwab Investment Management Inc. grew its position in Geron by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,450,382 shares of the biopharmaceutical company's stock valued at $20,205,000 after buying an additional 111,361 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GERN has been the subject of several recent analyst reports. Stifel Nicolaus reduced their target price on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. B. Riley lowered Geron from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and set a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. Scotiabank reduced their price target on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a report on Thursday, February 27th. Finally, HC Wainwright restated a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Geron currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.75.

Remove Ads

Geron Trading Up 4.0 %

Shares of NASDAQ GERN traded up $0.07 during midday trading on Friday, reaching $1.82. 26,066,277 shares of the stock were exchanged, compared to its average volume of 10,907,840. The stock has a 50 day moving average price of $2.45 and a 200-day moving average price of $3.50. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.16 billion, a P/E ratio of -5.69 and a beta of 0.53. Geron Co. has a 52-week low of $1.46 and a 52-week high of $5.34.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. Equities research analysts expect that Geron Co. will post -0.25 earnings per share for the current fiscal year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.